The REQUITE-AB study: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in breast cancer patients

Clinically significant side-effects from radiotherapy affect around a quarter of breast cancer patients and may impact considerably on outcomes from treatment. null An increasing number of replicated genetic associations for radiotherapy toxicity are being reported[1],[2]. null The EU-funded REQUITE consortium aims to validate genetic markers and clinical factors implicated in radiotoxicity. null The purpose of the REQUITE-AB project is to...